Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jinee Rizzo"'
Autor:
Jinee Rizzo, John G. Kuhn, Lisa A. Hammond, Garry Schwartz, Anthony W. Tolcher, Manuel Hidalgo, Eric K. Rowinsky, Amita Patnaik, S. Gail Eckhardt, Chris H. Takimoto, Samira Syed
Publikováno v:
Clinical Cancer Research. 10:6512-6521
Purpose: The purpose of this research was to assess the feasibility of administering Col-3, an oral chemically modified tetracycline derivative with potent inhibitory effects on matrix metalloproteinase activity and production, and recommend a dose o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18cf66acaf310c3c17a4855fa1bcb44
https://doi.org/10.1158/1078-0432.ccr-04-0804
https://doi.org/10.1158/1078-0432.ccr-04-0804
Autor:
K. Berg, Lisa A. Hammond, Jinee Rizzo, Amita Patnaik, Eric K. Rowinsky, D. D. Von Hoff, Garry Schwartz
Publikováno v:
Annals of Oncology. 14:775-782
Background The aim of this study was to assess the feasibility of administering bizelesin, a cyclopropylpyrroloindole with extraordinarily high potency as a bifunctional DNA-damaging agent and selectivity for specific AT-rich DNA sequences, as a sing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741214361832b5f86c84836a78a4adbc
https://doi.org/10.1093/annonc/mdg215
https://doi.org/10.1093/annonc/mdg215
Autor:
Leonel Ochoa, Garry Schwartz, Bahram Forouzesh, Lisa A. Hammond, Amita Patnaik, Chris H. Takimoto, Jinee Rizzo, Andrew Goetz, Anthony W. Tolcher, Joseph Kwiatek, Louis Denis, Jeffrey McGuire, Eric K. Rowinsky
Publikováno v:
Journal of Clinical Oncology. 21:148-157
Purpose: To assess the feasibility of administering camptothecin (CPT), the prototypic topoisomerase I inhibitor, as polyethylene glycol (PEG)-CPT, a macromolecule consisting of CPT conjugated to chemically modified PEG. The study also sought to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e0eae6edc188897108747007531d91
https://doi.org/10.1200/jco.2003.03.143
https://doi.org/10.1200/jco.2003.03.143
Autor:
Chris H. Takimoto, Louis Denis, S. Gail Eckhardt, Jinee Rizzo, Eric K. Rowinsky, Karen J. Ferrante, Lisa A. Hammond, John Nemunaitis, Anthony W. Tolcher, Daniel D. Von Hoff, Manuel Hidalgo, Sandra L Silberman, Lillian L. Siu, Carolyn D. Britten
Publikováno v:
Europe PubMed Central
PURPOSE: To assess the feasibility of administering OSI-774, to recommend a dose on a protracted, continuous daily schedule, to characterize its pharmacokinetic behavior, and to acquire preliminary evidence of anticancer activity. PATIENTS AND METHOD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::949b9904ecc6fd9016c4f9abdd1df40e
https://doi.org/10.1200/jco.2001.19.13.3267
https://doi.org/10.1200/jco.2001.19.13.3267
Autor:
Geoffrey R. Weiss, Daniel D. Von Hoff, John R. Eckardt, G. I. Rodriguez, Jinee Rizzo, Howard A. Burris, Lon Smith, Karla VanDenBerg, Suzanne M. Fields, John G. Kuhn
Publikováno v:
Cancer Chemotherapy and Pharmacology. 35:397-402
Preclinical studies of 2-chlorodeoxyadenosine (2-CdA) against solid tumors in the human tumor cloning assay and evidence that 2-CdA is active against slow-growing or resting tumor cells have stimulated interest in the clinical activity of this agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::502a841caeaf4c93817b437d5fb99517
https://doi.org/10.1007/s002800050253
https://doi.org/10.1007/s002800050253
Publikováno v:
Cancer Investigation. 17:118-120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29854eff5627f27679276bde3c95501e
https://doi.org/10.1080/07357909909011726
https://doi.org/10.1080/07357909909011726
Autor:
Shazli N, Malik, Lillian L, Siu, Eric K, Rowinsky, Linda, deGraffenried, Lisa A, Hammond, Jinee, Rizzo, Sarah, Bacus, Michael G, Brattain, Jeffrey I, Kreisberg, Manuel, Hidalgo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(7)
OSI-774 is an inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) currently in clinical development. In preclinical models, the antitumor activity of OSI-774 was directly related to its ability to inhibit the EGFR-TK. On the b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bba9e7dd03b818542ed200eec34d96f7
https://pubmed.ncbi.nlm.nih.gov/12855608
https://pubmed.ncbi.nlm.nih.gov/12855608
Autor:
Patrick Schöffski, Jos H. Beijnen, Jinee Rizzo, Jan H.M. Schellens, Sindy Jansen, Hilde Rosing, Nadja E. Schoemaker
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 775(2)
A high-performance liquid chromatography assay is described for the determination of the investigational anti-cancer drug 9-nitrocamptothecin (9-NC) and its metabolite 9-aminocamptothecin (9-AC) as the total of their lactone and carboxylate forms. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5f53a4bd78c8b683fb034d994c1e23
https://pubmed.ncbi.nlm.nih.gov/12113990
https://pubmed.ncbi.nlm.nih.gov/12113990
Autor:
Robert De Jager, E C E Charles Geyer, Thomas R. Johnson, Jinee Rizzo, Gail G. Eckhardt, Lisa A. Hammond, Ronald Drengler, Anthony W. Tolcher, Daniel D. Von Hoff, Garry Schwartz, Leslie Smetzer, Eric K. Rowinsky, John Coyle
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(17)
PURPOSE: To assess the feasibility of administering DX-8951f (exatecan mesylate), a water-soluble, camptothecin analog, as a 30-minute intravenous infusion daily for 5 days every 3 weeks, determine the maximum-tolerated dose (MTD) and pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a8cad4ea872458db261cee8320820dc
https://pubmed.ncbi.nlm.nih.gov/10963644
https://pubmed.ncbi.nlm.nih.gov/10963644
Autor:
Eric K. Rowinsky, Lon Smith, Ronald Drengler, Alison L. Hannah, Allison Thurman, Kevin R. Sweeney, John R. Eckardt, Maura Kraynak, Sharyn D. Baker, Gillian F. Cropp, S. Gail Eckhardt, Judy Moczygemba, Jinee Rizzo, Lisa A. Hammond, Daniel D. Von Hoff, Miguel A. Villalona-Calero, Geoffrey R. Weiss, John G. Kuhn
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(4)
PURPOSE: To evaluate the clinical feasibility and pharmacologic behavior of the platelet-derived growth factor (PDGF) tyrosine kinase inhibitor SU101, administered on a prolonged, intermittent dosing schedule to patients with advanced solid malignanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f279ddf4c424582d1b6e74b2e3bd6242
https://pubmed.ncbi.nlm.nih.gov/10561165
https://pubmed.ncbi.nlm.nih.gov/10561165